This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Zydus Cadila

Drug Names(s): ZYGK1

Description: ZYGK1 is an orally administered small molecule glucokinase activator. Glucokinase (GK) is the enzyme that acts as a glucose sensor in the pancreas and regulates glucose metabolism in the liver. When, circulating glucose levels rise above a certain threshold, the glucokinase enzyme enhances insulin release from pancreas and decreases glucose production in liver. In normal individuals, the pancreas secrete insulin in response to increased levels of glucose in the blood. In patients with Type 2 diabetes, there is a reduction of GK activity in the pancreas and the liver.

ZYGK1 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug